

Is Camrese 91 Day still in shortage in 2026? Get the latest update on availability, pricing, alternatives, and how to find it in stock near you.
If you rely on Camrese 91 Day for birth control, you've probably noticed it's been harder to find over the past few years. You're not imagining it — and you're not alone. Extended-cycle oral contraceptives like Camrese have been affected by supply disruptions that started around 2022 and have continued into 2026.
Here's what's happening, why it matters, and what you can do about it right now.
As of early 2026, Camrese 91 Day and several of its generic equivalents continue to experience intermittent availability issues. This isn't a complete nationwide shortage where the drug is entirely unavailable — it's more of a patchwork situation where some pharmacies have it and others don't.
The FDA's Drug Shortage Database tracks active shortages for medications in limited supply. Extended-cycle Levonorgestrel/Ethinyl Estradiol products have appeared on and off this list since 2022. Even when not listed as an official shortage, patients frequently report difficulty finding the medication at their local pharmacies.
The supply problems stem from several overlapping issues:
Fewer companies are producing extended-cycle oral contraceptives than a decade ago. When production is concentrated among a small number of manufacturers, any disruption — equipment maintenance, regulatory inspections, quality control issues — can affect the entire market.
The active pharmaceutical ingredients in Camrese (Levonorgestrel and Ethinyl Estradiol) require specialized sourcing. Global supply chain challenges have periodically limited the availability of these raw materials.
Extended-cycle contraceptives have become increasingly popular as more women choose to have fewer periods. This growing demand, combined with constrained supply, has created ongoing availability gaps.
Even when manufacturers produce adequate supply, distribution to individual pharmacies isn't always even. Chain pharmacies may prioritize higher-volume medications in their inventory, leaving Camrese understocked at many locations.
For a deeper look at these factors, read Why Is Camrese 91 Day So Hard to Find?
Cost remains a factor for many patients, especially if you need to switch pharmacies or explore different options:
If you're paying out of pocket, generic versions offer significant savings. Discount cards from GoodRx, SingleCare, and RxSaver can bring the price down further. For all the details, see our full guide on how to save money on Camrese 91 Day.
While no entirely new extended-cycle contraceptives have launched recently, patients have more generic options than before. The key alternatives include:
Additionally, some prescribers are helping patients use traditional 28-day pills in an extended or continuous fashion — skipping the placebo week — to achieve a similar effect to Camrese. This can open up a much wider range of available medications.
For a complete comparison, check out Alternatives to Camrese 91 Day.
Here's what's working for patients right now:
For the full playbook, read How to Find Camrese 91 Day in Stock Near You.
The Camrese 91 Day shortage situation in 2026 is frustrating but manageable. Supply continues to be inconsistent, but between generic alternatives, proactive planning, and tools like Medfinder, most patients can still access the extended-cycle contraception they need.
Stay informed, stay proactive, and don't hesitate to work with your prescriber if you're having trouble. For more information about the medication itself, visit our guide on What Is Camrese 91 Day?
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.